Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Fumarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 known ✓ | Q14145 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Fumarate SCHEMBL14966538 | 0.99 | HCAR2 (0.37) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL7926950 | 0.69 | — | — | |
| SCHEMBL28935347 | 0.63 | — | — | |
| Dimethyl Maleate SCHEMBL20854972 | 0.62 | NFE2L2 (0.93) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Maleate SCHEMBL25393211 | 0.61 | NFE2L2 (0.77) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Maleate SCHEMBL5607053 | 0.60 | NFE2L2 (0.87) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Fumarate SCHEMBL20562286 | 0.60 | NFE2L2 (0.87) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Fumarate SCHEMBL5607061 | 0.60 | NFE2L2 (0.87) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Maleate SCHEMBL75864 | 0.60 | NFE2L2 (1.00) | HCAR2KEAP1NFE2L2 | |
| Dimethyl Fumarate SCHEMBL41836 | 0.60 | NFE2L2 (1.00) | HCAR2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833496-B2 | Rapid cure silicone lubricious coatings | ETHICON, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220105502-A1 | Rapid Cure Silicone Lubricious Coatings | ETHICON, INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-11224869-B2 | Rapid cure silicone lubricious coatings | ETHICON, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10465094-B2 | Method of applying rapid cure silicone lubricious coatings | ETHICON, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10441947-B2 | Rapid cure silicone lubricious coatings | ETHICON, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180345262-A1 | Rapid Cure Silicone Lubricious Coatings | ETHICON, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180163090-A1 | Method of Applying Rapid Cure Silicone Lubricious Coatings | ETHICON, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20170028391-A1 | Rapid Cure Silicone Lubricious Coatings | ETHICON, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160348025-A1 | Rapid Cure Silicone Lubricious Coatings | ETHICON, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9434857-B2 | Rapid cure silicone lubricious coatings | ETHICON, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130122314-A1 | RAPID CURE SILICONE LUBRICIOUS COATINGS | ETHICON, INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122314-A1 | RAPID CURE SILICONE LUBRICIOUS COATINGS | ITCH, PELI1, MMS19 | KEAP1 4123/4885HCAR2 4195/4885NFE2L2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.